FISHAWACK
2e Creative , an internationally recognised healthcare marketing strategy firm focused on launching pharmaceutical and medical device products, has joined the Fishawack Group , after receiving investment from the global healthcare communications group. The 2e deal strengthens Fishawack as one of the largest independent healthcare communications organisations worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190801005540/en/
“2e has been on an exhilarating growth trajectory for the past several years,” 2e CEO Ross Toohey said. “We chose Fishawack over a host of other potential investors because their global footprint, expansive capabilities, and entrepreneurial culture represented the greatest advantage for our employees and clients. This is truly the next evolutionary leap for 2e and the brands we serve.”
Fishawack is a global healthcare communications group with offices in London, Oxford, Brighton and Manchester, UK, as well as Philadelphia, New York, and San Diego, USA; 2e adds to the group’s US footprint. The firm’s core strengths in medical communications, strategic consulting, and creative, fits nicely with 2e’s expertise in strategy, creative, digital marketing, sales training, and internal communications. With this breadth of capabilities, Fishawack and 2e can now support clients throughout the entire product development, launch, and growth lifecycle. With the 2e partnership, the Fishawack Group now boasts over 750 employees worldwide, making it among the largest independent healthcare agencies globally.
“Fishawack is one of the new generation of leaders in healthcare communications. We’re challenging the major agency networks by fostering a uniquely collaborative culture across our agency collective,” Fishawack CEO Oliver Dennis said. “We offer the capabilities, scale, and geographical coverage to offer healthcare brands a fresh, new type of partnership value. We’re excited about 2e’s portfolio, capabilities, and brilliant people. Ross has built a great entrepreneurial culture, and we can’t wait to work with the 2e team.”
This partnership is particularly notable for 2e because it comes on the heels of the agency’s appointment to the MM&M Top 100 Healthcare Agencies worldwide, as well as 2e’s three consecutive victories (2015, 2016, 2017) as MM&M “Healthcare Agency of the Year.” Between 2e and sister agencies Dudnyk , Carling Communications , Blue Latitude Health , and Healthcircle , the Fishawack Group is among the most award winning in the field of healthcare marketing.
“We’re very deliberate about the agencies we invest in,” Fishawack Group President Gail Flockhart said. “Clients demand seamlessly blended capabilities, so it’s important that we build collaborative allegiances across the Fishawack Group. It’s best for our clients and our people. 2e brings executive training and organisational optimisation capabilities to the group.”
Advisors to Fishawack included KPMG, Addleshaw Goddard LLP, and financial backers LDC and LGT Capital Partners. 2e’s advisors included Results International, Stoll Keenon Ogden PLLC, and Clifton Larson Allen.
About 2e Creative
Founded in 1999, 2e Creative is a launch and growth agency featuring Fortune 50 clients across pharma, medical device, and research biotech. The agency’s core competencies include branding, marketing strategy, digital marketing, sales training, and meeting/event production. 2e has over 150 employees and operations in Missouri, Indiana, Texas, and California.
About the Fishawack Group
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in the UK (Manchester, Oxford, London, and Brighton), the USA (Philadelphia, PA, New York, NY, and San Diego, CA), Switzerland (Basel), and India (Hyderabad).
Fishawack comprises two international divisions, Fishawack Medical Communications , developing and delivering services in the fields of medical communications, scientific engagement, publications, market access, strategic consultancy, and thought leader consultancy, and Fishawack Creative , offering strategic planning, creative development, advertising and promotion, and tactical execution.
We have built our reputation on excellence, creativity, and transparency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190801005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom